of nitrogenous waste products, fluid-electrolyte disturbances, and decreased diuresis, and hormonal changes (1-3). Therefore, AKI can be considered a complex, multifactorial syndrome, for which no consensus definition exists (4, 5) .
The Second International Consensus Conference of the Acute Dialysis Quality Initiative proposed and defined a set of diagnostic criteria for AKI in adults, termed the "Risk, Injury, Failure, Loss, End-stage renal disease" (RIFLE) score and published in 2004 (6) . Akcan-Arikan et al (7) later analyzed and modified these criteria for the use in children, thus creating the pediatric RIFLE or pediatric-modified RIFLE (pRIFLE) criteria. The authors found an 82% prevalence rate of AKI and a 21% mortality rate in patients with severe AKI (pRIFLE I + F).
Some studies of AKI in children have used the pRIFLE criteria, and what studies are available differ substantially in terms of prevalence and prognosis in their samples. A systematic review published in 2012 identified and analyzed 12 studies describing the application of RIFLE criteria in the pediatric population, which met predetermined inclusion and exclusion criteria (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Of these articles, 10 described the association of pRIFLE score with morbidity and mortality (7-9, 11, 13-16, 18, 19) . Only five of these studies compared the pRIFLE criteria with a validated illness severity score, and only one used the Pediatric Index of Mortality 2 (PIM2) scale (7, 9, 16, 18, 19) . Given the high worldwide prevalence of AKI in critically ill patients and its with mortality, further research is required, especially in the pediatric population (20) . Furthermore, it would be interesting to assess whether each category of AKI as defined by the pRIFLE criteria is associated with patient outcomes, with a view to developing measures for early identification of disease severity.
The present study sought to analyze the clinical and laboratory features and disease course of patients admitted to a PICU, with and without AKI as per pRIFLE criteria, classify the severity of AKI, and estimate the influence of the extent of renal involvement, as defined by pRIFLE scores, on patient outcomes.
MATERIALS AND METHODS
This was a retrospective cohort study of a database containing information on all patients admitted between August 2009 and July 2010 to the PICU of a tertiary referral center in Southern Brazil (Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul -PUCRS). The sample comprised all patients aged 29 days to 18 years who were admitted to the study unit during the period of analysis and met the criteria described by Pollack et al (21) : 1) PICU stay longer than 8 hours and 2) in case of death, a length of stay of 4 hours or longer. The criteria for exclusion were as follows: 1) failure to obtain data on any of the anthropometric variables of interest; 2) chronic kidney disease requiring dialysis; and 3) PICU admission for monitoring purposes alone (e.g., postcatheterization or bronchoscopy). The study was approved by the Research Ethics Committee of the institution where this work was performed. The informed consent requirement was waived for this study.
Clinical and demographic data were collected from patient charts. The parameters of interest included sex, age, weight, height, length of PICU stay, duration of mechanical ventilation, and duration of vasoactive drug therapy (dobutamine, dopamine, noradrenaline, vasopressin, adrenaline, or milrinone). Disease severity on PICU admission was estimated by the PIM2 scale (22) , which is used routinely at the study unit. Laboratory test results for each patient (albumin, lactate, blood glucose, and creatinine) were included in the database after an active search of patient charts. Estimated creatinine clearance (eCrCl) was calculated by means of the Schwartz formula (23). Patients were classified by their pRIFLE score at admission and their worst pRIFLE score during PICU stay. Baseline eCrCl was defined as 120 mL/min/1.73 m 2 , regardless of whether an actual baseline creatinine measurement was available (23, 24) . Patients with eCrCl within 25% of normal were classified as not having AKI. Patients with eCrCl decreased by 25-50% were classified as pRIFLE R, those with eCrCl decreased by 50-75% as pRIFLE I, and those with eCrCl decreased by 75% or more were classified as pRIFLE F. Estimated mortality (EM) was calculated as the sum of PIM2 values, whereas observed mortality (OM) was collected from the database. The Z statistic (as described by Flora) was used to compare similarities between OM and EM by means of the standard mortality ratio (SMR) (25) .
Statistical Analysis
The collected data were entered into a Microsoft Excel for Windows spreadsheet (Microsoft, Redmond, WA) and analyzed in SPSS 17.0 (SPSS, Chicago, IL).
Categorical variables were compared using the chi-square or Fisher exact tests as appropriate. Continuous variables were expressed as means and sd and compared with Student t test, if normally distributed, or expressed as medians and interquartile ranges and compared with the Mann-Whitney U test otherwise. Generalized linear models (Tweedie distribution with identity link function) were used to analyze the relationship between primary outcome (length of PICU stay) and predictive variables (sex, height, PIM2, and pRI-FLE). Flora's Z statistic was used to compare overall similarity between observed and expected mortality by means of the SMR (25) . Z values between +1.96 and -1.96 lack statistical significance and correspond to p value of greater than 0.01. The probability level below which the null hypothesis would be rejected was set at 5% (p < 0.05).
RESULTS
A total of 443 children were admitted to the study unit between August 1, 2009, and July 31, 2010. Of these patients, 15 did not meet the criteria for admission and 53 met the criteria for exclusion, for a final sample size of 375 patients (Fig. 1) . Table 1 describes the profile of the sample. Overall, 60% of patients were men and the median age was 24.2 months. The median (interquartile range) length of stay was 4.8 days (2.6-8.0 d). The PIM2-EM rate was 5.4%, whereas the actual OM rate was 5% (n = 20) (SMR = 0.98).
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At admission, 169 patients (45%) had AKI as per the pRIFLE criteria. Of these, 65% were classified as pRIFLE-R (n = 110), 32% as pRIFLE-I (n = 54), and 3% as pRIFLE-F (n = 5). At the time of PICU admission ( Table 2) , patients without AKI (n = 206) were older, heavier, and taller (p < 0.001) and had lower lactate levels (p < 0.006) than patients with AKI (n = 169). Furthermore, patients with AKI at admission had longer PICU stays (p < 0.001) than patients without AKI; however, there were no between-group differences in mortality or PIM2-predicted mortality.
When we pooled patients who had no AKI or were only at risk of renal injury (no AKI + pRIFLE-R) at admission (n = 316) and compared this group with patients who had severe AKI (pRIFLE-I + pRIFLE-F, n = 59) at admission, we found significant differences in age, weight, and height (p < 0.001), as well as increased duration of invasive mechanical ventilation, longer vasoactive drug use, and increased median PIM2 score in the latter group ( Table 3) .
Influence of AKI at Any Time During Hospitalization on the Clinical Course of PICU Patients
Of the 206 patients without AKI at the time of PICU admission, 28 (14%) progressed to pRIFLE R, 7 (3%) progressed to pRI-FLE I, and 2 (1%) progressed to pRIFLE F (Fig. 1) . On comparison of outcomes between patients with AKI at admission and patients who developed AKI during PICU stay, the only variable that differed significantly between groups was length of stay. Patients who developed AKI during PICU stay had a median length of stay of 7.2 days (4.9-15.5 d) versus a median length of stay of 5.1 days (3.5-10.0 d) among those who already had AKI at admission (p = 0.031).
To assess the influence of renal impairment at any time during hospitalization on clinical course, we compared patients who did not develop AKI (n = 169; 54% men) and those who had AKI (n = 206; 63% men) as per the pRIFLE criteria. Patients with acute renal impairment at any time during hospitalization (Table 4) exhibited significant differences in age, weight, and height (p < 0.001), had prolonged length of stay, and increased mortality (2.4% vs 7.8%; p < 0.02). Median mortality risk predicted by PIM2 scores was also significantly different between the non-AKI (PIM2, 0.9 [0.4-2.8]) and AKI (PIM2, 1.6 [0.5-5.3]) groups (p = 0.006). The observed and expected mortality rates were similar both in the non-AKI group (SMR, 0.77; Flora's Z = 0.56; p > 0.01) and in the AKI group (SMR, 1.06; Flora's Z = -0.30; p > 0.01). The observed and expected mortality rates were similar in both groups (SMR, 0.77 in the non-AKI group and 1.05 in the AKI group).
Multiple logistic regression analysis revealed that AKI at any time during hospitalization, diagnosed by the pRIFLE criteria, and PIM2 score were independent risk factors for prolonged PICU stay.
Pooled analysis of patients who did not develop AKI and those who reached only pRIFLE class R (non-AKI + R) during hospitalization (n = 297; 59% men) versus those who reached pRIFLE classes I or F at any time during hospitalization (n = 78; 67% men) revealed even greater between-group differences. In addition to significant differences in age, weight, and height (p < 0.001), we found worse renal impairment was associated with longer PICU stay, longer duration of invasive mechanical ventilation, longer vasoactive drug use, and increased mortality (14.1% vs 3% in the non-AKI + R group; p < 0.001). The median risk of death predicted by the PIM2 score also differed significantly between these groups (p < 0.001). However, the EM rate (as predicted by PIM2) was slightly lower than the OM rate in patients with more severe renal impairment (EM, 8.7; OM, 11; SMR, 1.25; Flora's Z, -1.08). Patients who reached pRIFLE class I or F at any time during hospitalization exhibited higher median lactate levels (1.6 vs 1.3; p < 0.003) and lower median albumin levels (3.1 vs 3.3; p = 0.009).
Separate analyses of each AKI category occurring at any time during hospitalization (Table 5) showed that patients with pRIFLE-F renal impairment had a three-fold increase in length of stay when compared with patients who did not develop AKI (12.4 vs 3.3 d; p < 0.001), as well as markedly increased mortality (53.8% vs 2.4%). Furthermore, in this group of patients with the most severe renal impairment, the OM rate was double the EM rate estimated by PIM2 scores (SMR, 2.19; Flora's Z, -3.6).
DISCUSSION
In this retrospective study of the characteristics and clinical course of PICU patients with AKI as defined by the pRIFLE criteria, we found that 1) renal impairment is a common finding in critically ill pediatric patients, both at the time of admission (45%) and during PICU stay (55%); 2) pRIFLE class has an impact on the mortality risk of PICU patients as estimated by the PIM2 instrument. Notably, in patients with severe AKI, the PIM2 tended to underestimate the risk of death; 3) severe AKI (defined as pRIFLE class I + F) during a PICU stay is an independent predictor of increased morbidity and mortality.
In the first study published on the pRIFLE criteria, the prevalence of AKI at the time of admission was 42%, rising to 82% throughout hospitalization (7) . Similar results were observed in our sample, with AKI rates of 45% at admission and 55% at any time during hospitalization. In other studies, the prevalence of AKI has ranged from 36% to 58%, which demonstrates that acute renal injury is a very common complication in critically ill children (8, 26, 27) .
In our sample, a large portion of patients already had AKI at the time of admission, and others developed AKI during their PICU stays. It is evident that AKI is a dynamic, multifactorial, and progressive disease. The high prevalence of AKI at admission suggests that future studies that seek to assess risk factors for development of this complication should include data obtained prior to PICU admission and appears to indicate an unmet need for strict monitoring of renal function in the emergency department.
In our sample, the severity of renal impairment as defined by the pRIFLE criteria interfered with the risk of death as estimated by the PIM2 score. In previous studies by Akcan-Arikan et al (7), Palmieri et al (9) , and Zappitelli et al (18) , the pRIFLE classification was adequately associated with the Pediatric Risk of Mortality prognostic score. In these three studies, patients with AKI had a higher risk of death than patients without AKI. However, these studies did not evaluate the relationship between prognostic scores and mortality in different classes of AKI. Prior work by Basu et al (28) notes that the PIM2 and other "severity of illness scores" are inadequate as predictors of AKI progression. In the present study, PIM2 tended to underestimate mortality in patients with severe AKI (pRIFLE I + F). In pRIFLE class F patients, the difference was significant; mortality was very high in this group of patients (53.8%) and far exceeded that predicted by the PIM2 score (SMR, 2.19; Flora's Z, -3.6).
The underestimation of mortality by PIM2 in patients with severe AKI suggests that its prognostic model is insufficiently sensitive for this patient population. This may be explained by the fact that PIM2 calculation does not provide for renal function. We suggest that future updates to the PIM2 scoring system should include renal function parameters. In our sample, the mortality rate of patients who had severe AKI (pRIFLE I + F) at any time during hospitalization was nearly five-fold that observed in patients with pRIFLE class R or without AKI (14.1% vs 3%; p < 0.001). When analysis was restricted to patients who reached pRIFLE class F at any time during hospitalization, the difference in mortality was even greater (53.8% vs 3.5% in the overall sample). This finding is consistent with the literature. Akcan-Arikan et al (7) reported a 21% mortality rate in patients with severe AKI, and in the study by Palmieri et al (9) of pediatric burn patients, the mortality rate of the pRIFLE F group was 50%. A 2013 study by Bresolin et al (29) reported high mortality in patients classified as pRIFLE R, unlike in the present study, where we found a gradual increase in mortality with worsening renal function as determined by the pRIFLE score and a greater concentration of deaths in the pRIFLE F group, which, in our opinion, appears closer to reality. Regarding the current pRIFLE criteria, our study shares some limitations with the prior research of Uchino et al (30) and Ostermann and Chang (3) . in adult patients, namely, our sample did not contain any information on urinary output; creatinine alone was used for patient classification. As reported by Hoste and Kellum (31) in an adult sample, patients classified as pRIFLE R using creatinine as the sole criterion actually have more severe renal impairment than patients in pRIFLE class R as defined by urinary output alone. In the study by Akcan-Arikan et al (7), children with AKI as determined by the creatinine criterion had a higher mortality rate and were more likely to have severe renal impairment (pRIFLE I and F) than children whose pRIFLE classification was based on urinary output. Only five of 12 studies included in a 2012 systematic review used urinary output-based criteria (7-10, 14, 15) . Therefore, we believe that creatinine-based pRIFLE classification is better able to identify the severity of AKI. Nevertheless, we cannot rule out a possible change in our results if urinary output data had been included.
Another limitation of our study was our decision to use a predetermined baseline eCrCl value of 120 mL/min/1.73 m 2 for all patients, even those for whom recent creatinine levels (measured within 3 months of admission) were available. The use of an estimated GFR of 120 mL/min/1.73 m 2 as baseline may have artifactually increased the prevalence of AKI in our study by including, among others, patients with functional AKI (formerly known as prerenal azotemia). However, due to methodological limitations, we cannot determine how many of these patients had persistent AKI at 72 hours. Although AKI was associated with poorer outcomes in our sample, we cannot rule out the possibility that our findings would have been different if we had taken actual preadmission creatinine levels into account, used a baseline eCrCl of 100 mL/min/1.73 m 2 , or conducted an analysis that included persistent AKI within the first 72 hours.
Another limitation of this study concerns the use of the original rather than the "revised" Schwartz equation. We decided against the use of the revised formula because, as noted by the investigators who developed it, the revised equation was only tested in children with a GFR of 15-75 mL/min/1.73 m 2 . Because our population included patients without AKI, this precluded the use of the revised formula, which is not validated for the use in patients with normal or near-normal renal function (32) .
CONCLUSIONS
Thus, we conclude that the pRIFLE system for classification of AKI has excellent clinical utility and should enter routine use as a tool for identification of patients with poor prognosis.
Furthermore, we conclude that a high proportion of patients admitted to PICUs exhibit AKI at the time of admission, and that the presence of AKI at any time during PICU hospitalization is associated with worse outcomes. Consequently, the prognostic scoring systems used in the PICU setting (PIM and Pediatric Risk of Mortality) could be updated to include AKI in their models.
Further pediatric studies comparing pRIFLE classes and prognostic scores are warranted, as is research into the possibility of detecting AKI prior to PICU admission.
